Maxigen Biotech Inc.

TWSE:1783 Voorraadrapport

Marktkapitalisatie: NT$3.8b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Maxigen Biotech Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ching-Ting Chen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO3.1yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur3.3yrs

Recente managementupdates

Recent updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Analyse CEO-vergoeding

Hoe is Ching-Ting Chen's beloning veranderd ten opzichte van Maxigen Biotech's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

NT$147m

Mar 31 2024n/an/a

NT$150m

Dec 31 2023n/an/a

NT$166m

Sep 30 2023n/an/a

NT$191m

Jun 30 2023n/an/a

NT$192m

Mar 31 2023n/an/a

NT$163m

Dec 31 2022n/an/a

NT$139m

Sep 30 2022n/an/a

NT$110m

Jun 30 2022n/an/a

NT$99m

Mar 31 2022n/an/a

NT$87m

Dec 31 2021NT$1mNT$540k

NT$88m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Ching-Ting redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de TW markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Ching-Ting te vergelijken met de prestaties van het bedrijf.

CEO

Ching-Ting Chen

3.1yrs

Tenure

NT$1,322,000

Compensatie

Ms. Ching-Ting Chen is Institutional Director of TCI Co. Ltd. from June 25, 2024 and serves as Head of Research & Design Center since February 5, 2020. She is General manager of TCI CO., Ltd.She has been...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Ching-Ting Chen
GM & Representative Director2.9yrsNT$1.32m0.11%
NT$ 4.2m
Yung-Hsiang Lin
Chairman of the Board3.3yrsgeen gegevensgeen gegevens
Tsiu-Yuan Li
Representative Director9.3yrsgeen gegevensgeen gegevens
Chen-Chen Fu
Representative Director3.3yrsgeen gegevensgeen gegevens
Song Yuan Liao
Independent Director3.3yrsgeen gegevensgeen gegevens
Shi-Ming Li
Independent Director3.3yrsgeen gegevensgeen gegevens
Zeng Zhong Ming
Independent Director3.3yrsgeen gegevensgeen gegevens
Tsong-Jieh Chiou
Directorno datageen gegevensgeen gegevens
Shih-Ming Lai
Directorno datageen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 1783 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).